Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.15.6387

Prognostic Significance of the Peripheral Blood Absolute Monocyte Count in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma Receiving Systemic Chemotherapy  

Lin, Gui-Nan (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital)
Jiang, Xiao-Mei (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital)
Peng, Jie-Wen (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital)
Xiao, Jian-Jun (Department of Medical Oncology, Zhongshan Hospital of Sun Yat-sen University, Zhongshan City People's Hospital)
Liu, Dong-Ying (Department of Clinical Oncology, Jiangmen Hospital of Sun Yat-sen University, Jiangmen City Central Hospital)
Xia, Zhong-Jun (State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.15, 2014 , pp. 6387-6390 More about this Journal
Abstract
Background: The prognostic significance of the circulating absolute monocyte count (AMC) in patients with locally advanced hepatocellular carcinoma (HCC) is uncertain. This study was designed to assess the association of circulating AMC with survival outcomes in patients diagnosed with locally advanced or metastatic HCC receiving systemic chemotherapy. Materials and Methods: Between January 1, 2005 and December 30, 2012, locally advanced or metastatic HCC patients who had Child-Pugh stage A or B disease and received systemic chemotherapy were retrospectively enrolled. Patient features including gender, age, extrahepatic metastasis, Child-Pugh stage, serum alpha-fetoprotein(AFP) level and AMC were collected to investigate their prognostic impact on overall survival(OS). Results: A total of 216 patients were eligible for the study. The optimal cut-off value of AMC for OS analysis was $0.38{\times}10^9/L$. Median OS was 5.84 months in low-AMC group (95% confidence interval [CI], 5.23 to 6.45), and 5.21 months in high-AMC group (95% CI, 4.37 to 6.04; p=0.003). In COX multivariate analysis, elevated AMC remained as an independent prognostic factor for worse OS (HR, 1.578; 95% CI, 1.120 to 2.223, p=0.009). Conclusions: Our results indiicate that circulating AMC is confirmed to be an independent prognostic factor for OS in patients with locally advanced or metastatic HCC receiving systemic chemotherapy.
Keywords
Citations & Related Records
Times Cited By KSCI : 8  (Citation Analysis)
연도 인용수 순위
1 Sasaki A, Iwashita Y, Shibata K, et al (2006). Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. Surgery, 139, 755-64.   DOI
2 Schimanski CC, Bahre R, Gockel I, et al (2006). Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer, 95, 210-7.   DOI   ScienceOn
3 Takai H, Kato A, Kato C, et al (2009). The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int, 29, 1056-64.   DOI
4 Wang Z, Wu XL, Zeng WZ et al (2013). Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma. Asian Pac J Cancer Prev, 14, 691-4.   과학기술학회마을   DOI   ScienceOn
5 Werno C, Menrad H, Weigert A, et al (2010). Knockout of HIF-$1\alpha$ in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis, 31, 1863-72.   DOI
6 Yang HI, Lu SN, Liaw YF, et al (2002). Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 347, 168-74.   DOI   ScienceOn
7 Yang Y, Nagano H, Ota H, et al (2007). Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery, 141, 196-202.   DOI   ScienceOn
8 Yu Q, Yu XF, Zhang SD, et al (2013). Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 5735-40.   과학기술학회마을   DOI   ScienceOn
9 Zheng YB, Zhao W, Liu B, et al (2013). The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib. Asian Pac J Cancer Prev, 14, 5527-31.   과학기술학회마을   DOI   ScienceOn
10 Zhu XD, Zhang JB, Zhuang PY, et al (2008). High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol, 26, 2707-16.   DOI   ScienceOn
11 Benetti A, Berenzi A, Gambarotti M, et al (2008). Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res, 68, 8626-34.   DOI
12 Castello G, Scala S, Palmieri G, et al (2010). HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol, 134, 237-50.   DOI
13 Chen J, Li G, Meng H, et al (2012). Up regulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas. Cancer Immunol Immunother, 61, 101-8.   DOI
14 Cheng AL, Kang YK, Chen Z, et al (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol, 10, 25-34.   DOI   ScienceOn
15 Cui L, Liu XX, Jiang Y, et al (2012). Comparative study on transcatheter arterial chemoembolization, portal vein embolization and high intensity focused ultrasound sequential therapy for patients. Asian Pac J Cancer Prev,13, 6257-61.   DOI   ScienceOn
16 Dai J, Tang K, Xiao W, et al (2014). Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3369-75.   과학기술학회마을   DOI
17 Farazi PA and DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87.   DOI   ScienceOn
18 Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pac J Cancer Prev, 13, 743-52.   과학기술학회마을   DOI   ScienceOn
19 Gomaa AI, Hashim MS, Waked I (2014). Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One, 9, e90929.   DOI
20 He SL, Shen J, Sun XJ, et al (2013). Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol, 19, 4552-8.   DOI
21 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
22 Kuang DM, Peng C, Zhao Q, et al (2010). Tumor-activated monocytes promote expansion of IL-17-producing CD8+ T cells in hepatocellular carcinoma patients. J Immunol, 185, 1544-9.   DOI
23 Lee YY, Choi CH, Sung CO, et al (2012). Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol, 124, 92-7.   DOI
24 Li J, Jiang R, Liu WS, et al (2013). A large cohort study reveals the association of elevated peripheral blood lymphocyte-tomonocyte ratio with favorable prognosis in nasopharyngeal carcinoma. PLoS One, 8, e83069.   DOI
25 Liu H, Pan Z, Li A, et al (2008). Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol, 5, 373-8.   DOI
26 Lok AS, Seeff LB, Morgan TR, et al (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology, 136, 138-48.   DOI   ScienceOn
27 Louafi S, Boige V, Ducreux M, et al (2007). Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer, 109, 1384-90.   DOI
28 Ma WJ, Wang HY and Teng LS (2013). Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol, 11, 212.   DOI
29 Ma TC, Shao HB, Xu Y, et al (2013). Three treatment methods via the hepatic artery for hepatocellular carcinoma-a retrospective study. Asian Pac J Cancer Prev, 14, 2491-4.   과학기술학회마을   DOI   ScienceOn
30 Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9.   과학기술학회마을   DOI   ScienceOn
31 Peng SH, Deng H, Yang JF, et al (2005). Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. World J Gastroenterol, 11, 6521-4.
32 Qin S, Bai Y, Lim HY, et al (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol, 31, 3501-8.   DOI   ScienceOn
33 Huang JJ, Li YJ, Xia Y, et al (2013). Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma. BMC Cancer, 13, 222.   DOI